Zegfrovy
Pronunciation: zeg-FROH-vee
Generic name: sunvozertinib
Dosage form: oral tablets (150 mg, 200 mg)
What is Zegfrovy?
Zegfrovy is used to treat non-small cell lung cancer (NSCLC) that is locally advanced or has metastasized and with an abnormal epidermal growth factor receptor (EGFR) gene, in adults whose disease has worsened while on or after chemotherapy that contains platinum. It is an oral tablet taken 1 time a day.
Zegfrovy is a targeted drug that works by blocking EGFR, a protein that promotes cancer growth. It specifically targets EGFR exon 20 insertion mutations found in some lung cancers. In laboratory clinical trials, it effectively stopped cancer cell growth and shrank tumors in animal models with these specific mutations. Zegfrovy belongs to the drug class called kinase inhibitors.
Zegfrovy (sunvozertinib) gained FDA approval on July 2, 2025. There is no generic.
FDA approvals and uses
Zegfrovy is used to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
- This approval is under accelerated approval based on the overall response rate and duration of response. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Your healthcare provider will perform a test to make sure that Zegfrovy is right for you.
It is not known if Zegfrovy is safe and effective in children.
Side effects
The most common side effects of Zegfrovy include:
- diarrhea
- rash
- decreased appetite
- mouth sores
- feeling very tired
- nausea
- infected skin around the nail
- vomiting
- constipation
- muscle or joint pain
- itchy skin
- dry skin
- urinary tract infection
- stomach-area pain
- decreased weight.
The most common severe abnormal laboratory test results with Zegfrovy include:
- decreased white blood cell and red blood cell counts
- decreased potassium and salt (sodium) levels
- increased pancreas enzyme levels
- increased liver enzyme levels
- increased creatine kinase levels
- increased magnesium levels.
Zegfrovy may affect fertility in females and males, which may affect your ability to have a child. Talk to your healthcare provider if this is a concern for you.
Serious side effects and warnings
Zegfrovy may cause the following serious side effects:
- Lung problems. Zegfrovy can cause lung problems that can be severe and life-threatening. Symptoms may be similar to those of lung cancer. Tell your healthcare provider right away if you develop new or worsening symptoms of lung problems during treatment with Zegfrovy, including shortness of breath or trouble breathing, cough, or fever.
- Stomach and intestinal (gastrointestinal) problems. Zegfrovy can cause stomach and intestinal problems that can be severe, including diarrhea, nausea, and vomiting. Tell your healthcare provider right away if you get any of these symptoms during treatment with Zegfrovy. Your healthcare provider may prescribe medicines as needed, or recommend drinking fluids or other treatments, to help treat your symptoms.
- Skin problems. Zegfrovy can cause severe skin rashes. Use alcohol-free (such as isopropanol-free or ethanol-free) moisturizing cream during treatment with Zegfrovy. Avoid use of irritating skin products, such as Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with Zegfrovy if you develop certain side effects. skin products containing retinol or retinoic acid, and benzoyl peroxide. Tell your healthcare provider right away if you develop any skin reactions, including small, raised skin bumps that look like acne or itchy skin.
- Eye problems. Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you develop new or worsening eye problems during treatment with Zegfrovy. You should not use contact lenses until your eye symptoms are checked by a healthcare provider and for at least 1 week after your eye symptoms have resolved. Tell your healthcare provider right away if you develop any new or worsening symptoms of eye problems, including:
- eye pain
- increased tears
- eye crusting
- eye redness
- discharge from your eyes
- blurred vision or vision problems
- light sensitivity
- eye irritation
- loss of vision
- feeling like something is in your eyes
- dry eyes.
These are not all of the possible side effects of Zegfrovy. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Related/similar drugs
Before taking
Before taking Zegfrovy, tell your healthcare provider about all of your medical conditions, including if you:
- have a history of eye or vision problems
- are pregnant or plan to become pregnant
- are breastfeeding or plan to breastfeed
Pregnancy
Zegfrovy can harm your unborn baby. Females who are able to become pregnant:
- Your healthcare provider should do a pregnancy test before you start treatment with Zegfrovy.
- You should use an effective form of non-hormonal birth control (contraception) during treatment with Zegfrovy and for 2 weeks after your last dose of Zegfrovy.
Talk to your healthcare provider about birth control methods that might be right for you during this time. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Zegfrovy.
Males who have female partners who can become pregnant:
- You should use effective birth control (contraception) during treatment with Zegfrovy and for 2 weeks after your last dose of Zegfrovy.
Breastfeeding
It is not known if Zegfrovy passes into your breast milk. Do not breastfeed during treatment with Zegfrovy and for 2 weeks after your last dose of Zegfrovy. Talk to your healthcare provider about the best way to feed your baby during treatment with this medicine.
How should I take Zegfrovy?
Take Zegfrovy exactly as your healthcare provider tells you. Do not change your dose or stop taking this medicine unless your healthcare provider tells you to.
- Take Zegfrovy 1 time a day at the same time each day.
- Take with food.
- Swallow the tablets whole. Do not split, crush, chew, or dissolve the tablets.
Dosing information
Dose of Zegfrovy for NSCLC in Adults
- 200 mg orally once daily taken with food.
What happens if I miss a dose?
If you miss a dose of Zegfrovy, take it as soon as you remember within 12 hours. If it has been more than 12 hours, skip the missed dose and take your next dose at your regularly scheduled time.
If you vomit after taking a dose of Zegfrovy, do not take an extra dose. Take your next dose at your regularly scheduled time.
What other drugs will affect this medicine?
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Zegfrovy may affect the way other medicines work and other medicines may affect how Zegfrovy works. Especially tell your healthcare provider if you take:
- Strong CYP3A inhibitors, such as ketoconazole (antifungal), itraconazole (antifungal), clarithromycin (antibiotic), or ritonavir (HIV medication). Avoid concomitant use. If concomitant use cannot be avoided, reduce the Zegrovy dose
- Strong and moderate CYP3A inducers, such as rifampin (antibiotic), phenytoin (seizure medication), carbamazepine (seizure medication), St. John's Wort (herbal supplement), efavirenz (HIV medication), modafinil (wakefulness drug), or bosentan (pulmonary hypertension drug). Avoid concomitant use. If concomitant use cannot be avoided, increase the Zegfrovy dose
- P-gp or BCRP substrates, such as digoxin (heart medication), dabigatran (blood thinner), rosuvastatin (cholesterol drug), or metformin (diabetes drug). Monitor for increased adverse reactions during concomitant use.
- Hormonal Contraceptives, such as birth control pills, contraceptive patches, vaginal rings, and hormonal IUDs. Avoid concomitant use.
This is not a complete list of interactions. You can use the Drugs.com Drug Interaction Checker to check your other medications against Zegfrovy for interactions.
Storage
Store Zegfrovy at room temperature between 68°F to 77°F (20°C to 25°C).
Keep out of the reach of children.
Ingredients
Active ingredient: sunvozertinib
Pronunciation: zeg-FROH-vee
Generic name: sunvozertinib
Dosage form: oral tablets (150 mg, 200 mg)
Company
Pronunciation: zeg-FROH-vee
Generic name: sunvozertinib
Dosage form: oral tablets (150 mg, 200 mg)
References
More about Zegfrovy (sunvozertinib)
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.